Moderna products by NPV worldwide 2021 | Statista

As of August 2021, the net present value of Moderna's COVID-19 vaccine, Spikevax, was around 20.2 billion U.S. dollars. This statistic illustrates the net present value (NPV) of Moderna products worldwide as of August 2021, in million U.S. dollars.

Net Present Value (NPV) of Moderna products worldwide as of August 2021 (in million U.S. dollars)

Product (therapy area, development phase)	NPV in million U.S. dollars
Spikevax (COVID-19 vaccine, marketed)	20,199
mRNA-1647 (Cytomegalovirus vaccine, phase 2)	2,484
mRNA-1345 (RSV vaccine, phase 1)	2,002
mRNA-2752 (solid tumors/lymphoma, phase 1)	775
mRNA-1653 (hMPV/PIV3 vaccine, phase 1)	529
AXD8601 (Myocardial ischaemia therapy, phase 2)	282
mRNA-3927 (Propionic acidaemia therapy, phase 1)	276
mRNA-1893 (Zika vaccine, phase 1)	252
mRNA-3283 (Phenylketonuria therapy, preclinical)	208
mRNA-4157 (Personalised cancer vaccine, phase 2)	97
mRNA-1944 (Chikungunya anti-viral, phase 1)	5
mRNA-5671 (Kras vaccine, phase 1)	1

Loading statistic...

Download

Source

Show detailed source information?

Register for free

Already a member?

Sources

Use Ask Statista Research Service

Release date

August 2021

More information

Region

Worldwide

Survey time period

as of August 2021

Citation formats

Other statistics on the topic
mRNA technology

Revenue of Moderna Inc. from 2016 to 2023 (in million U.S. dollars)

Pharmaceutical Products & Market

Moderna's revenue 2016-2023

Forecasted sales of select COVID-19 vaccines worldwide in 2021 and 2022 (in billion U.S. dollars)

Pharmaceutical Products & Market

Forecasted sales of select COVID-19 vaccines worldwide 2021-2022

Revenue of BioNTech SE from 2017 to 2023 (in million euros)

Pharmaceutical Products & Market

Revenue of BioNTech 2017-2023

World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2022

Pharmaceutical Products & Market

Top 50 global pharmaceutical and biotech companies by R&D intensity in 2022

Access all statistics starting from $2,388 USD yearly ^*

* For commercial use only

For single users

$0 USD

Always free

Access limited to Free Statistics. Premium Statistics are not included.

Free Statistics

Based on your interests

For single users

$199 USD

per month, billed annually ¹

Free Statistics
Premium Statistics

For teams of up to 5 people

$959 USD

per month, billed annually ¹

Free + Premium Statistics
Reports
Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " mRNA technology "

The most important statistics

The most important statistics

The most important statistics

The most important statistics

The most important statistics

The most important statistics

Other statistics that may interest you mRNA technology

Overview

5

Research and development

5

COVID-19

6

Leading companies

4

Focus: Moderna

5

Focus: BioNTech

4

Further related statistics

11

Further Content: You might find this interesting as well

Statistics

Topics

mRNA technology

Biotechnology industry in Germany

Biotechnology in Europe

Coronavirus (COVID-19) vaccines and treatments

All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

For single users

$0 USD

Always free

Access limited to Free Statistics. Premium Statistics are not included.

Free Statistics

Based on your interests

For single users

$199 USD

per month, billed annually ¹

Free Statistics
Premium Statistics

For teams of up to 5 people

$959 USD

per month, billed annually ¹

Free + Premium Statistics
Reports
Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Learn more about how Statista can support your business.